New therapies for chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease (COPD) is the most common lung disease, carrying a significant mortality and morbidity. None of the therapeutic interventions currently available alter the progression of the disease. As our understanding of the basic mechanisms of alveolar destruction and airflow limitation improves, new targets are identified that may eventually result in treatment options which will affect the progression of this disease. In this review, we discuss some of the novel therapeutic options recently developed that may have an impact on the management of COPD. Future directions in research and development of pharmacological agents based on improved understanding of COPD are also discussed.
Krishna
Ganesh
G
Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, USA.
Sankaranarayanan
Viji
V
Chitkara
Rajinder K
RK
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D010102:Oxygen Inhalation Therapy; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000473:pathology / Q000534:rehabilitation / Q000601:surgery; D016540:Smoking Cessation
D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents